Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Current Assets (2016 - 2025)

BioCorRx (BICX) has disclosed Current Assets for 16 consecutive years, with $814468.0 as the latest value for Q4 2025.

  • Quarterly Current Assets rose 590.25% to $814468.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $814468.0 through Dec 2025, up 590.25% year-over-year, with the annual reading at $814468.0 for FY2025, 590.25% up from the prior year.
  • Current Assets hit $814468.0 in Q4 2025 for BioCorRx, up from $35000.0 in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $2.0 million in Q1 2021 to a low of $35000.0 in Q3 2025.
  • Historically, Current Assets has averaged $478567.7 across 5 years, with a median of $348761.5 in 2023.
  • Biggest YoY gain for Current Assets was 590.25% in 2025; the steepest drop was 90.09% in 2025.
  • Year by year, Current Assets stood at $228326.0 in 2021, then surged by 38.8% to $316910.0 in 2022, then crashed by 40.96% to $187119.0 in 2023, then crashed by 36.94% to $117996.0 in 2024, then surged by 590.25% to $814468.0 in 2025.
  • Business Quant data shows Current Assets for BICX at $814468.0 in Q4 2025, $35000.0 in Q3 2025, and $527483.0 in Q2 2025.